|Day Low/High||29.73 / 31.04|
|52 Wk Low/High||4.67 / 25.07|
Aetna now offers commercial coverage of Exact Sciences' Cologuard test.
Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity
Jim Cramer is bullish on T-Mobile, Box and Treehouse Foods. He's bearish on Verizon and Best Buy.
Jim Cramer knows this administration is pro-business, but Washington isn't the only place building business and market strength.
Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.
Cologuard offers health plans an opportunity to increase screening & improve quality ratings
Biotech shares have gained from takeovers in that sector.
- Preliminary revenues between $99.0 million and $99.5 million for 2016, a year-over-year increase of 150 percent;
Cologuard Covered for 70 Percent of Addressable Population
Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening Test and Compliance Service
Respected diagnostics industry expert will help lead efforts to capitalize on market opportunity for Cologuard
Here's a window into what institutional investors may be doing and how to profit from that.
America's veterans, military personnel and their families provided access to non-invasive, at-home colon cancer screening option without copay
Exact Sciences (EXAS) stock is gaining on Monday after the National Committee for Quality Assurance updated its guidelines on colorectal cancer screening tests.
Cologuard offers opportunity for health plans, systems & providers to improve quality ratings
Here's a look at two stocks that are trending higher and two that are ripe for short-selling.